Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice – results from the prospective German TMK cohort study.

N Marschner, T Fietz, J Rauh, A Nusch, U Söling, M Frank, L Kruggel, M Jänicke, 2017.

The Breast, Volume 36, S45 https://doi.org/10.1016/S0960-9776(17)30688-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ABC4 / Journal:
TMK
2017
Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE).

Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017.

Oncol Res Treat, 40(suppl 3)(P577), 162-163.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
KORALLE
2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017.

BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: BMC Cancer
PASO
2017
Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., Cancer), 2017.

Breast Cancer Res Treat 1–12. doi:10.1007/s10549-017-4534-8

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
TMK
2017
Was können Registerdaten bei der Nutzenbewertung leisten?

Marschner, N., Jänicke, M., 2017.

Ärztezeitung, Schriftenreihe Interdisziplinäre Plattform zur Nutzenbewertung “Lücken in der Evidenz – was leisten Registerdaten?” Heft 5, September 2017, ISSN 2364-916X

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Hefte der Interdisziplinären Plattform zur Nutzenbewertung
Registerübergreifend
2017
Die Bedeutung von klinischen Tumorregistern.

Marschner, N., Kaiser-Osterhues, A., 2017.

Im Focus Onkologie 20(9), 42–44. doi:10.1007/s15015-017-3513-6

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Im Focus Onkologie
Registerübergreifend
2017
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study.

Verschuer, U. von, Schnell, R., Tessen, H.W., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419-1. doi: 10.1016/j.lungcan.2017.07.031

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Lung Cancer
TLK
2017
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study.

Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017.

The Breast 34, 122–130. doi:http://dx.doi.org/10.1016/j.breast.2017.05.014

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: The Breast
TMK
2017
Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO)

Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017.

ESGO7–0321 (PS19)

Abstract

Indikation: Other, Sonstige / Veranstaltung: ESGO / Journal: -
OTILIA
2017
Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO.

Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017.

J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
NABUCCO
2017